Business

Biotech, pharma, and money in science

Prostate Cancer
Biotech

Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

By Adam Feuerstein

Brain map
Biotech

New chemical eyed in fight vs. Alzheimer’s

By Jonathan Saltzman — Boston Globe

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

23andMe kits
Business

How 23andMe thinks about genetic privacy in the age of forensic genealogy and Facebook’s woes

By Rebecca Robbins and Damian Garde

Health

The EKG is only a start. Apple wants to seize the market for patient monitoring

By Casey Ross

Robert Desimone
Business

Science cities, stealing IP, and hyper-competition: a China hand’s intelligence briefing

By Sharon Begley

IVF frozen samples
Business

A new venture fund will invest in reproductive medicine. Here’s what’s worth watching in the field

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Pharmalot

Pharmalittle: FDA approves a record number of generics; Bristol-Myers’ Opdivo fails lung cancer study goal

By Ed Silverman

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Zodiac Killer DNA
Business

‘We are increasingly exposed’: New studies show how easy it is to identify people using genetic databases

By Rebecca Robbins

Jungeun Lee
Biotech

In the red-hot race to fill biotech jobs, benefits abound

By Jonathan Saltzman — Boston Globe

Business

U.S. crackdown on foreign investments could cool Asia’s desire for U.S. biotech

By Damian Garde

Acute Promyelocytic Leukemia
Biotech

Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy

By Damian Garde

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Nick Leschly - Bluebird Bio
Biotech

Surprise! Bluebird Bio’s beta thalassemia gene therapy is already under review in Europe

By Adam Feuerstein

Sarepta - Cambridge
Biotech

Hop, skip, jump. Sarepta’s Duchenne gene therapy delivers early muscle function improvements

By Adam Feuerstein

Humira injection
Health

Caregivers or marketers? Nurses paid by drug companies facing scrutiny as whistleblower lawsuits mount

By Ed Silverman and Karen Weintraub

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Lab tests
Biotech

Momenta lays off half of its employees, including key executives

By Jonathan Saltzman — Boston Globe

Business

Pharma tries to cash in on migraine market by making new drugs free, for now

By Damian Garde

Paxil
Business

In the race to use genetic tests to predict whether antidepressants will work, science might be getting left behind

By Rebecca Robbins

Mail bag
Biotech

You have questions about how to best analyze clinical trials. We have answers

By Adam Feuerstein and Sharon Begley

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Lessons Learned
Lessons Learned

Lessons Learned: Here’s how you job hunt while postdoc-ing overseas

By Megha Satyanarayana

Andy Slavitt
Health

Andy Slavitt wants health technology to benefit the disenfranchised. He’s raised $115 million to make it happen

By Casey Ross

STAT Live

Webinar archive: How to interpret clinical trial results like a pro

By Sharon Begley and Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Fish oil capsules
Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Generic medicine bottle
Politics

Generic drug makers face ‘a silent crisis,’ FDA official says, and raising prices could help

By Ike Swetlitz

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy